iShares Evolved U.S. Innovative Healthcare ETF (IEIH)
|Ex-Dividend Date||Sep 24, 2021|
|Day's Range||34.63 - 34.98|
|Inception Date||Mar 21, 2018|
The investment seeks to provide access to U.S. companies with innovative healthcare exposure, as classified using a proprietary classification system. The fund invests, under normal circumstances, at least 80% of its net assets in U.S. listed common stock of large-, mid- and small-capitalization pharmaceutical and biotechnology companies. It will hold common stock of those companies that fall into the Innovative Healthcare Evolved Sector which have economic characteristics that have been historically correlated with companies traditionally defined as pharmaceutical and biotechnology companies. The fund is non-diversified.
Top 10 Holdings56.36% of assets
|Johnson & Johnson||JNJ||9.34%|
|Sep 24, 2021||$0.12464||Sep 30, 2021|
|Jun 10, 2021||$0.08647||Jun 16, 2021|
|Mar 25, 2021||$0.10641||Mar 31, 2021|
|Dec 14, 2020||$0.09933||Dec 18, 2020|
|Sep 23, 2020||$0.09635||Sep 29, 2020|
|Jun 15, 2020||$0.0631||Jun 19, 2020|
The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.
Reflecting what it considers the vast potential of life sciences companies, Bain Capital is making another huge bet on the industry. The Boston-based investment firm has raised $1.9 billion in a new fun...
Some biotech and pharmaceutical ETFs are gaining on Tuesday despite news that Johnson and Johnson's coronavirus vaccine has been halted in over two dozen states, after the Food and Drug Administration r...
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development.
Johnson & Johnson beat the second-quarter earnings and revenue estimates but warned on competition from generics and biosimilars that could impact its third-quarter results.